Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ION-682884 in Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
jRCT2061220044Phase 3Active, not recruiting
- Sponsor
- Ionis Pharmaceuticals
- Start
- Oct 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ION-682884 with Placebo (2 arms). Primary endpoint: Composite cardiovascular death and recurrent cardiovascular clinical events up to Week 140. Started Oct 2022; status: active, not recruiting.
02
Drugs
eplontersen
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2061220044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220044.